VYSTAR : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)

OVERVIEW

Vystar LLC, the predecessor to the Company, was formed February 2, 2000, as a
Georgia limited liability company by Travis W. Honeycutt. Operations under the
LLC entity were focused substantially on the research, development and testing
of the Vytex® Natural Rubber Latex ("NRL") process, as well as attaining
intellectual property rights. In 2003, the Company reorganized as Vystar
Corporation, a Georgia corporation, at which time all assets and liabilities of
the limited liability company became assets and liabilities of Vystar
Corporation, including all intellectual property rights, patents and trademarks.



We are the creator and exclusive owner of the innovative technology to produce
Vytex NRL. This technology reduces antigenic protein in natural rubber latex
products to virtually undetectable levels in both liquid NRL and finished latex
products. The process also removes many of the naturally occurring non-rubber
particles superfluous to end product function, resulting in a cleaner latex base
material. We have introduced Vytex NRL, our "ultra-low protein" natural rubber
latex, throughout the worldwide marketplace that uses NRL or latex substitutes
as a component of manufactured products. Natural rubber latex is used in an
extensive range of products including balloons, textiles, footwear and clothing
(threads), adhesives, foams, furniture, carpet, paints, coatings, protective
equipment, sporting equipment, and especially health care products such as
condoms, surgical and exam gloves. We produce Vytex through licensing agreements
and have introduced Vytex NRL into the supply channels with aggressive, targeted
marketing campaigns directed to the end users.



We transitioned from a development stage company to the operating stage during
the last quarter of 2009. During the period of 2010 to 2015, our financial
condition and results of operations have experienced substantial fluctuations as
we provided introductory pricing in 2010 and then began to switch to a licensing
rather than a toll model in 2011. Our licensing model will continue in 2019 for
the raw material business and we will continue our focus in 2019 onward on the
licensing contracts associated with the foam and furniture offerings.
Accordingly, the financial condition and results of operations reflected in our
historical financial statements are not expected to be indicative of our future
financial condition and results of operations.



We believe that the key for increased Vytex NRL product acceptance is to focus
on companies seeking solutions to production challenges or ways to differentiate
their product offering. Vystar's technical team has been successful in
developing customized formulations to meet specific manufacturer needs. Some of
these formulations will become new line extensions. Vystar is becoming less of a
raw material provider and more of a technology innovator through its technical
consultation and formulation activities.



In addition to this technology focus, we are determined to have the "made with
Vytex" claim added to products made using various forms of Vytex NRL. To help
drive this effort, we're focusing on products that benefit from Vytex NRL low
non-rubber features. As part of this effort, we are working with a licensee to
launch a line of foam core products used in various bedding products including
pillows, mattresses and mattress toppers.



In January 2015, Vystar announced that it had entered into an exclusive
agreement with NHS Holdings, LLC ("NHS") to distribute mattresses, mattress
toppers and pillows made with its multi-patented Vytex NRL raw material. NHS is
a distribution company led by Steven Rotman of Rotmans, who as of December 18,
2017 is the CEO of Vystar, that focuses on innovative, sustainably sourced,
eco-friendly material and technologies for use in furnishings and other markets.
Our Vytex NRL fits the needs of this unique new distributor, which has already
attracted such firms as mattress manufacturer Gold Bond, that was formed in 1899
to manufacture and then distribute mattresses, toppers and pillows along with a
plan to reach specific segments of the United States by targeting other
manufacturers. Vystar has focused on these segments since 2015 and will continue
into 2019 as we display at furniture and mattress conventions and attend and
sell at sleep products meetings such as the ISPA 2016 (International Sleep
Products Association) held in Orlando, FL, the ISPA 2017 in Tampa, FL and the
ISPA 2018 in Charlotte, NC. Vystar will also continue to develop specialty
versions of Vytex NRL after presenting to the International Latex Conference in
Akron, OH in July 2016 and 2017 and sending out samples for lab trials. Vystar
is currently producing Vytex thread samples for an entry into the thread
marketplace. In September 2016, the Vystar Board of Directors voted to end the
January 2015 agreement with NHS and replace it with a global exclusive for foam
manufactured with Vytex and sold into the home furnishings industry. This change
reflects the global nature of the mattress, topper and pillow businesses.



In April of 2018, Vystar acquired the assets of NHS executing on the first part
of the Company's vision to move into direct product offerings made from
Vytex®latex. NHS was the exclusive U.S. distributor of Vystar's Vytex® natural
rubber latex foam to manufacturers for use in over 200 home furnishings
products, including mattresses, toppers, pillows and upholstery, sold through
multiple channels. This acquisition provides Vystar with roll packing and
cutting equipment to support our bedding manufacturing partners, while lowering
the cost of Vytex to the manufacturer by eliminating the middleman.



                                      31

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS

        OF OPERATIONS (Continued)




OVERVIEW (Continued)

Now unified under the Vytex brand, we anticipate developing additional product offerings and solidifying partnerships with multiple major manufacturing partners throughout the home furnishings industry. We anticipate our new offerings will include cushions and padding for use in seating and other products which we believe will achieve higher margins.

In May of 2018, Vystar acquired substantially all of the assets of UV Flu
Technologies, Inc. ("UV Flu"), formerly traded on the OTC under the ticker UVFT,
whose patented ViraTech™ UV light air purification technology destroys greater
than 99% of airborne bacteria, viruses and other microorganisms and virtually
eliminates concentrations of odors and volatile organic compounds ("VOCs").



As part of Vystar's mission to offer eco-friendly, sustainable materials and
products that create a better environment for consumers and workers throughout
the product lifecycle, UV Flu is an excellent counterpart to our Vytex materials
and Vytex bedding products. Vystar products will help create a perfect natural
sleep environment starting with Vytex bedding made from the purest latex in the
world and UV Flu's RxAir™ air purifier ensuring every breath is free of harmful
pathogens, VOCs and odors.



UV Flu products use 48 inches of high-intensity germicidal UV lamps that destroy
bacteria, viruses and other germs instead of just trapping them, setting it
apart from ordinary air filtration units. RxAir is one of the few UV air
purifiers that have been proven in independent EPA- and FDA- certified testing
laboratories to destroy on the first pass 99.6% of harmful airborne viruses and
bacteria. In addition to inactivating airborne viruses that cause influenza
(flu) and colds, RxAir's device disarms the airborne pathogens that cause MRSA
(staph), strep (whooping cough), tuberculosis (TB), measles, pneumonia and a
myriad of other antibiotic-resistant and viral infections.

UV Flu's product line includes:

? RxAir™ Residential Filterless Air Purifier

? UV400 ™ FDA cleared Class II Filterless Air Purifier

? RX3000™ Commercial FDA cleared Class II Air Purifier

Vystar acquired all UV Flu intellectual property and multiple patents, product
lines, tooling, FDA clearances, research data, websites and other assets related
to the business for the purchase price of $975,000 or 27,918,000 shares of
Vystar restricted common stock which may not be assigned or sold by UV Flu

for
12 months.



Vystar will continue production of UV Flu product lines with BOI, a world-class
manufacturer. Vystar plans to sell RxAir residential and commercial units via
distributors, online and through retail channels. Vystar has been selling the
RxAir units after receiving a substantial number of units by container in the
first quarter. In addition, master distributors and manufacturers
representatives have signed contracts with Vystar. The first large scale
distributor order was placed and paid for in May 2019.



Vystar is assembling the distribution network to relaunch sales of UV400 and
Rx3000 units to the healthcare and medical markets, which UV Flu had ceased due
to a lack of sales force, distribution and cash flow constraints. Once
production and sales are firmly re-established, Vystar expects that the air
purification products will produce margins of approximately 75%.



UV Flu's products have world class engineering, are made to the highest quality
standards and are extremely effective in settings ranging from homes to offices,
healthcare facilities, salons, restaurants, and nursing homes.



About RxAir



RxAir promotes a healthy lifestyle through the use of its innovative, patented
ViraTech air purification technology, thereby improving the quality of life of
each and every customer. Independently tested by EPA- and FDA-certified
laboratories, the RxAir has been proven to destroy greater than 99% of bacteria
and viruses and reduce concentrations of odors and VOCs. The RxAir uses
high-intensity germicidal UV lamps that destroy bacteria and viruses instead of
just trapping them, setting it apart from ordinary air filtration units. RxAir®
and ViraTech® are registered trademarks of Vystar Corp. For more information,
visit http://www.RxAir.com.



In the first quarter, Vystar also made huge strides in enhancing Vystar's large
patent portfolio, continuing the outstanding work from previous management.
Today, Vystar has 28 patents encompassing many continents. Vystar will be adding
significant resources in the near term to enforce and prosecute infringers of
our patents ensuring Vystar has the ability to fully collect on its proprietary
Vytex investment.





                                      32

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS

        OF OPERATIONS (Continued)




OVERVIEW (Continued)



About FEC

In May of 2019, Vystar Corporation executed a patent assignment to purchase the
assets of Fluid Energy Conversion Inc., ("FEC"), which consists primarily of
U.S. and foreign rights to US Patent No. 7,897,121. The assets were purchased
for 2,500,000 shares of common stock of Vystar Corporation (current approximate
value of $100,000).



FEC is a global green energy company whose patented and proprietary technologies
harness sound energy in unique ways to destroy bacteria and viruses, improve
water processing and irrigation, and enhance chemical reactions. FEC has married
the science of sound energy, called sono- chemistry, with molecular fluid
mechanics for the development of applications to more effectively kill
pathogens, improve combustion efficiency, overcome the issues of hardwater
mineral build up, and enhance vaporization of liquids. FEC's science and
technology has been proven in multiple studies with major corporations.
Currently, FEC technology R&D is underway on the following initiatives:

? Vystar plans to apply FEC technology to increase pathogen killing efficiency,

reduce size and cost of Vystar's RxAir air purifiers.

? FEC technology expected to be used to negate viruses and bacteria using sound

energy in a highly proprietary manner.

? Vystar plans to apply FEC technology to vape pens to improve substance delivery

   and control dosage.

? FEC technology offers numerous eco-friendly product initiatives already in

   development in metering, energy, water purification, and medical uses.

? A water filtration enhancement device in prototype stage to improve dialysis

   efficiency for those affected by renal failure.






About Rotmans



On July 18, 2019, the Company acquired a controlling interest in Rotmans for
$2,030,000, comprised of 25% in notes payable over 4-8 years and 75% in notes
convertible into common shares. Rotmans and the Company are exploring a number
of initiatives relating to environmentally friendly product development and
distribution that will utilize the access to the capital markets afforded by
this transaction.

Rotmans, the largest furniture and flooring store in New England and one of the
largest independent furniture retailers in the U.S., encompassing over 200,000
square feet in Worcester, Mass., and employing 150 people, was founded and has
been under the leadership of the Rotman family for the past 50 years. Rotmans is
expected to add approximately $30 million annually to Vystar's top line revenue
and enable Vystar to capitalize on the infrastructure already in place for
accounting, retail sales facilities and staff, customer service, warehousing,
and delivery. Additionally, it will offer significant marketing and advertising
opportunities for all of Vystar's brands to Rotmans' thousands of existing
customers. The acquisition is expected to dramatically increase Vystar
shareholder value and liquidity through improved access to capital markets as
well as lay the groundwork for future eco-friendly initiatives. As CEO of both
Rotmans and Vystar, Steven Rotman will provide continuity of management and
customer- focused values for Rotmans and Vystar.



During the third quarter of 2019, the Company focused on the completion of the
Rotmans acquisition and subsequent integration of the Company's sales,
marketing, warehousing, and accounting functions. New systems, controls, and
procedures are being added as well as a host of additional staff and software.
The Company has invested significantly in the completion of the merger and has
committed a considerable amount of staff resources, most of which is a one-time
cost. We believe the combined capabilities of our two organizations create an
opportunity to amplify the authentic and special brands we have built and
accelerate the pursuit of our vision to build the most innovative and
inspirational home furnishings brand. Together, we will create a dramatic path
toward long term growth and value for our brand, people, customers, and
suppliers. We are thrilled to add this prestigious brand to Vystar's platform,
as it not only positions Vystar as an authority in one of the most important and
profitable rooms of the home - the bedroom - but also creates a showcase for
Vystar. There are very few opportunities to acquire a well-managed, growing
company such as Rotmans, especially given Vystar's previous size. This
partnership represents a key opportunity to drive long-term growth and value
creation for our shareholders.



                                      33

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS

        OF OPERATIONS (Continued)




RESULTS OF OPERATIONS



Comparison of the Three Months Ended September 30, 2019 with the Three Months
Ended September 30, 2018



                                                   Three Months Ended September 30,
                                         2019             2018          $ Change        % Change

                                                             CONSOLIDATED

Revenue                              $  6,040,201     $    187,543     $ 5,852,658        3,120.7 %

Cost of revenue                         3,378,220          182,937       3,195,283        1,746.7 %

Gross profit (loss)                     2,661,981            4,606       2,657,375       57,693.8 %

Operating expenses:

General and administrative              3,871,282          477,705       3,393,577          710.4 %

Loss from operations                   (1,209,301 )       (473,099 )      (736,202 )        155.6 %

Other income (expense):
Loss on settlement of debt               (339,875 )              -        (339,875 )        100.0 %
Interest expense                         (195,142 )       (476,847 )       281,705          -59.1 %
Change in fair value of derivative
liabilities                                     -          (95,365 )        95,365         -100.0 %
Other income                                7,956                -           7,956          100.0 %

Total other expense, net                 (527,061 )       (572,212 )        45,151           -7.9 %

Net loss                               (1,736,362 )     (1,045,311 )      (691,051 )         66.1 %

Net loss attributable to
noncontrolling interest                    63,802                -          63,802          100.0 %

Net loss attributable to Vystar $ (1,672,560 ) $ (1,045,311 ) $ (627,249 ) 60.0 %

Revenues



Revenues for the three months ended September 30, 2019 and 2018 from the Company
were $6,040,201 and $187,543, respectively, for an increase of $5,852,658 or
3,120.7%. The significant increase in revenues was due to an increase in
operations as a whole due to multiple acquisitions since March 31, 2018.



The Company reported a significant increase in gross income to $2,661,981 for
the three-month period ended September 30, 2019 compared to gross income of
$4,606 for the three-month period ended September 30, 2018, an increase of
$2,657,375. The cost of revenue for the three months ended September 30, 2019
and 2018 was $3,378,220 and $182,937, respectively, an increase of 1,746.7%. The
increase is due to the greater inventory needs primarily from the acquisitions
of Rotmans, UV Flu and NHS.



Operating Expenses



The Company's operating expenses consist of general and administrative expenses.
General and administrative expenses consist primarily of compensation and
support costs for management and administrative staff, and for other general and
administrative costs, including professional fees related to accounting,
finance, and legal services as well as other operating expenses. The Company's
operating expenses were $3,871,282 and $477,705 for the three months ended
September 30, 2019 and 2018, respectively, an increase of $3,393,577 or 710.4%.
The increase is mainly due to accounting and legal fees related to shareholder
note conversions and the Rotmans transaction. Operating expenses included
patents, latex consultants, accounting fees, and employee expenses.



                                      34

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS

        OF OPERATIONS (Continued)

RESULTS OF OPERATIONS (Continued)

Other Income (Expense)



Other expense for the three months ended September 30, 2019 was $527,061, which
primarily consisted of a loss on settlement of convertible notes payable of
$339,875 and interest expense of $195,142. This compares to other expense of
$572,212, for the three months ended September 30, 2018, which includes interest
expense of $476,847 and change in the fair value of derivative liabilities of
$95,365. The reason for the decrease in other expense for the three months ended
September 30, 2019 was related to prior financings.



Net Loss

Net loss attributable to Vystar was $1,672,560 and $1,045,311 for the three
months ended September 30, 2019 and 2018, respectively, an increase of $627,249.
The larger net loss the Company experienced in the quarter ended September 30,
2019 versus the same period in 2018 was primarily attributable to accounting and
legal fees related to shareholder note conversions and the Rotmans transaction.



Comparison of the Nine Months Ended September 30, 2019 with the Nine Months
Ended September 30, 2018



                                                     Nine Months Ended September 30,
                                         2019             2018           $ Change         % Change

                                                              CONSOLIDATED

Revenue                              $  6,417,431     $    250,516     $  6,166,915          2,461.7 %

Cost of revenue                         3,789,186          251,402        3,537,784          1,407.2 %

Gross profit (loss)                     2,628,245             (886 )      

2,629,131 -296,741.6 %

Operating expenses:

General and administrative              6,823,395        2,970,664        3,852,731            129.7 %

Loss from operations                   (4,195,150 )     (2,971,550 )     (1,223,600 )           41.2 %

Other income (expense):
Loss on settlement of debt               (327,433 )              -         (327,433 )          100.0 %
Interest expense                         (335,208 )       (579,597 )        244,389            -42.2 %
Change in fair value of derivative
liabilities                            (1,044,250 )        (95,365 )       (948,885 )          995.0 %
Other income                                7,802          326,237         (318,435 )          -97.6 %

Total other expense, net               (1,699,089 )       (348,725 )     (1,350,364 )          387.2 %

Net loss                               (5,894,239 )     (3,320,275 )     (2,573,964 )           77.5 %

Net loss attributable to
noncontrolling interest                    63,802                -           63,802            100.0 %

Net loss attributable to Vystar $ (5,830,437 ) $ (3,320,275 ) $ (2,510,162 )

           75.6 %




Revenues



Revenues for the nine months ended September 30, 2019 and 2018 from the Company
were $6,417,431 and $250,516, respectively, for an increase of $6,166,915, or
2,461.7%. The increase in revenues was due to an increase in operations as a
whole due to multiple acquisitions since March 31, 2018.



For the Company, gross profit increased from a gross loss of $886 for the nine
months ended September 30, 2018 to gross profit of $2,628,245 for the nine
months ended September 30, 2019, an increase of $2,629,131. Cost of revenue for
the nine months ended September 30, 2019 and 2018 was $3,789,186 and $251,402,
respectively, an increase of $3,537,784. The increase is mainly due accounting
and legal fees related to the greater inventory needs primarily from the
acquisitions of UV Flu, NHS, and Rotmans.



                                      35

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS

        OF OPERATIONS (Continued)

RESULTS OF OPERATIONS (Continued)

Operating Expenses



The Company's operating expenses consist of general and administrative expenses.
General and administrative expenses consist primarily of compensation and
support costs for management and administrative staff, and for other general and
administrative costs, including professional fees related to accounting,
finance, and legal services as well as other operating expenses. The Company's
operating expenses were $6,823,395 and $2,970,664 for the nine months ended
September 30, 2019 and 2018, respectively, an increase of $3,852,731 or 129.7%
due primarily to accounting and legal fees related to shareholder note
conversions and the Rotmans transaction. Operating expenses included patents,
latex consultants, accounting fees, and employee expenses.



Other Income (Expense)

Other expense for the nine months ended September 30, 2019 was $1,699,089, which
consisted of interest expense of $335,208, loss on settlement of convertible
notes payable of $327,433, change in fair value of derivative liabilities of
$1,044,250 and other income of $746. This compares to other expense of $348,725
for the nine months ended September 30, 2018, which includes $326,237 related to
forgiveness of debt and interest expense of $579,597. The reason for the
increase in other expense for the nine months ended September 30, 2019 was due
to a loss recognized on the conversion of debt instruments into shares of common
stock, in addition to the increase in the fair value of derivative liabilities
related to the convertible notes payable. The decrease in interest expense for
the nine months ended September 30, 2019 was due to the settlement of the CMA
note in the third quarter.



Net Loss

Net loss attributable to Vystar was $5,830,437 and $3,320,275 for the nine
months ended September 30, 2019 and 2018, respectively, an increase of
$2,510,162 or 75.6%. The larger net loss the Company experienced in the nine
months ended September 30, 2019 versus the same period in 2018 was primarily
attributable to the unusual and infrequent loss recognized from fair value
changes to the derivative liabilities and the loss on settlement of debt.

LIQUIDITY AND CAPITAL RESOURCES

The Company's financial statements are prepared using the accrual method of
accounting in accordance with U.S. GAAP and have been prepared on a going
concern basis, which contemplates the realization of assets and the settlement
of liabilities in the normal course of business. However, we have incurred
significant losses and experienced negative cash flow since inception. At
September 30, 2019, the Company had cash of $64,233 and a deficit in working
capital of approximately $3.3 million. Further, at September 30, 2019, the
accumulated deficit amounted to approximately $39.2 million. We use working
capital to finance our ongoing operations, and since those operations do not
currently cover all of our operating costs, managing working capital is
essential to our Company's future success. Because of this history of losses and
financial condition, there is substantial doubt about the Company's ability to
continue as a going concern.



A successful transition to profitable operations is dependent upon obtaining
sufficient financing to fund the Company's planned expenses and achieving a
level of revenue adequate to support the Company's cost structure. Management
plans to finance future operations using cash on hand, increased revenue from
Vytex license fees that now also include the Company's association with foam
cores made from Vytex used in mattresses, mattress toppers and pillows, and
stock warrant exercises from existing shareholders. The Company has also focused
the efforts of key internal employees on the goal of creating efficiencies in
each department, including purchasing, marketing, inventory control,
advertising, accounting, warehousing and customer service.



There can be no assurances that we will be able to achieve projected levels of
revenue in 2019 and beyond. If we are not able to achieve projected revenue and
obtain alternate additional financing of equity or debt, we would need to
significantly curtail or reorient operations during 2020, which could have a
material adverse effect on our ability to achieve our business objectives, and
as a result, may require the Company to file bankruptcy or cease operations. The
financial statements do not include any adjustments relating to the
recoverability and classification of recorded asset amounts or amounts
classified as liabilities that might be necessary should the Company be forced
to take any such actions.



The Company's future expenditures will depend on numerous factors, including:
the rate at which we can introduce and license Vytex NRL raw material and the
foam cores made from Vytex to manufacturers and subsequently retailers; the
costs of filing, prosecuting, defending and enforcing any patent claims and
other intellectual property rights; market acceptance of the Company's products,
services and competing technological developments; and the success of our
efforts to reduce expenses in our retail furniture business. As the Company
expands its activities and operations, cash requirements are expected to
increase at a rate consistent with revenue growth after the Company has achieved
sustained revenue generation.



                                      36

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS

        OF OPERATIONS (Continued)

LIQUIDITY AND CAPITAL RESOURCES (Continued)

Sources and Uses of Cash



For the nine months ended September 30, 2019 and 2018, net cash used in
operations was $1,090,903 and $1,071,437, respectively. The negative cash flow
from operations for the nine months ended September 30, 2019 and 2018 resulted
primarily from accounting and legal fees related to the NHS, UV Flu, FEC and
Rotmans transactions.

Net cash used in investing activities of $10,019 for the nine months ended
September 30, 2019 was for costs associated with patent and trademark fees and
website development costs compared to net cash used in investing activities of
$4,423 for the nine months ended September 30, 2018 for costs related to patent
and trademark fees.

Net cash provided by financing activities of $1,115,092 for the nine months
ended September 30, 2019 consisted of mainly equity and debt arrangements. Net
cash provided by financing activities for the nine months ended September 30,
2018 was $1,253,550, which included equity and debt arrangements.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that may be reasonably likely to have a current or future material effect on our financial condition, liquidity, or results of operations.

DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS

Our Management's Discussion and Analysis contains not only statements that are
historical facts, but also statements that are forward-looking (within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934). Forward-looking statements are, by their very
nature, uncertain and risky. These risks and uncertainties include
international, national and local general economic and market conditions;
demographic changes; our ability to sustain, manage, or forecast growth; product
development, introduction and acceptance; existing government regulations and
changes in, or the failure to comply with, government regulations; adverse
publicity; competition; fluctuations and difficulty in forecasting operating
results; changes in business strategy or development plans; business
disruptions; the ability to attract and retain qualified personnel; the ability
to protect technology; and other risks that might be detailed from time to time
in our filings with the Securities and Exchange Commission.



Although the forward-looking statements in this Quarterly Report reflect the
good faith judgment of our management, such statements can only be based on
facts and factors currently known by them. Consequently, and because
forward-looking statements are inherently subject to risks and uncertainties,
the actual results and outcomes may differ materially from the results and
outcomes discussed in the forward-looking statements. You are urged to carefully
review and consider the various disclosures made by us in this report and in our
other reports as we attempt to advise interested parties of the risks and
factors that may affect our business, financial condition, and results of
operations and prospects.

© Edgar Online, source Glimpses